美常安联合得舒特治疗腹泻型肠易激综合征的疗效观察

Efficacy of Medilac-s on Diarrhea-Dominant Irritable Bowel Syndrome

目的探讨美肠安治疗腹泻型肠易激综合征的疗效。方法将60例患者随机分为2组,A组30例,口服得舒特50 mg,每天3次。B组30例,口服美常安500 mg,每天3次,得舒特50 mg,每天3次,疗程4周。观察大便性状评分,腹部综合症状等级评分和疗效评价。结果治疗4周后,两组Bristol评分均较治疗前明显提高,腹部症状评分较治疗前都有明显下降,B组改善更明显。两组之间的治疗效果比较有明显差异,B组疗效更好。结论美肠安治疗腹泻型肠易激综合征安全有效。

Objective To evaluate the clinical efficacy of pinaverium bromid alone or combined with medilac-s in relieveng symptoms in patients with diarrhea-dominart irritable bowel syndrome（IBS-D）. Methods 60 patients diagnosed as IBS- D according to the Rome Ⅲ criteria by a simple stool description were randomly divided into two groups. Group A（30 patients） received only pinaverium bromid alone （50 mg rid）. Group B （30 patients）received pinaverium bromide combined with medilac-s （500 mg tid）. Main outcomes assessment included the days of diarrhea, abdominal pain relief, the Bristol stool form scale, the symptomatic scores and curative effect at the end of 4 weeks. Results 4 weeks later, the Bristol stool from scale, the symptomatic score significantly improved in both groups comparing with baseline. In group B improvement was better than group A. There was significant difference of efficiency between group A and group B. Conclusion Medilac-s is an effective and safe agent for treatment of IBS-D.